This week's news from the unlisted shares on Eqvor: Sigicom joins the platform, Hasko Invest delivers a very strong second quarter with 58 per cent growth, Storsala carries out its largest directed share issue to date and Kaunis Iron opens talks with LKAB about ore deliveries. Plus A3P Biomedical's quarter, Instabee's new parcel lockers and a new episode of Vägen till Exit.
Sigicom — the measurement technology company is now on Eqvor
Sigicom is now on Eqvor and the share is open for trading. The company develops, manufactures and sells the INFRA system — wireless sensors and data loggers that monitor vibrations, noise and other environmental disturbances at construction, infrastructure and mining projects. Since 2024, services have been the larger revenue stream, a revenue base that follows the number of ongoing measurement projects rather than individual hardware deals.
| Sigicom in brief | |
|---|---|
| Founded in Tullinge by Christer Svensson | 1981 |
| Revenue 2025 | 266 MSEK |
| Change vs 2024 | +7.6% |
| Equity ratio | 78% |
The founding family Rehnström/Svensson holds 41 per cent of the shares, and the investment company Traction has been an owner since 1997 with just under 21 per cent. The share is connected to Euroclear, the securities register, and is held in your own custody account.
Source: Eqvor and Sigicom, annual report 2025.
Hasko Invest — a very strong second quarter
The growth comes with rising, not squeezed, margins — all three segments improved their profitability, with Regional Products at the top with a 33.5 per cent margin. Of the revenue growth, 13 per cent was organic.
| MSEK | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net revenue | 380.4 | 240.3 | +58% |
| Adjusted EBITA | 93.2 | 44.4 | +110% |
| Adjusted EBITA margin | 24.5% | 18.5% | +6.0 pp |
| Profit for the period | 60.1 | 19.8 | +204% |
During the quarter, three companies were acquired, as well as about 20 per cent of the shares in the subsidiary do88 from the minority owners — six acquisitions in total during the half-year, with combined annual revenue of about 306 MSEK. In June the group was refinanced through an updated credit agreement with Swedbank totalling 800 MSEK.
Source: Hasko Invest, interim report for the second quarter of 2026.
A3P Biomedical — the study stronger than the sales
Net revenue fell 61 per cent, which the company mainly explains by sales being conducted in the form of pilot projects and by the 2025 figures having been heavily affected by project-based studies.
| TSEK | Q2 2026 | Q2 2025 |
|---|---|---|
| Net revenue | 2,825 | 7,159 |
| Profit before tax | −24,081 | −18,436 |
| Cash and cash equivalents incl. short-term investments | 120,097 | 192,455 |
At the same time, a study was published during the quarter in the Annals of Internal Medicine in which the Stockholm3 blood test identified 90 per cent of the men with aggressive prostate cancer, with a specificity of 89 per cent. In the US the dialogue continues — a second FDA guidance meeting was held in April, and talks with CMS about reimbursement began during the summer.
Source: A3P Biomedical, interim report for the second quarter of 2026, and a study published in the Annals of Internal Medicine.
Storsala — its largest directed share issue to date
The issue was subscribed by both existing and new shareholders and is intended to strengthen the company's acquisition capacity — in June Storsala agreed its largest acquisition to date, a commercial property portfolio in the Stockholm region with an underlying property value of about SEK 1.2 billion.
| Storsala in brief | |
|---|---|
| Directed new share issue, largest to date | 158 MSEK |
| Equity raised since 2025, three directed issues | approx. 400 MSEK |
| Bond loan, admitted to trading around 26 August | 300 MSEK |
At the same time, the bond prospectus has been approved by the Swedish Financial Supervisory Authority (Finansinspektionen): the senior secured bond loan of SEK 300 million is expected to be admitted to trading on Nasdaq Stockholm's corporate bond list around 26 August.
Source: Storsala, press release.
Instabee — parcel lockers move into residential areas
Instabee is launching a new generation of free-standing parcel lockers built for residential areas: solar and battery powered, installed without a fixed power connection or extensive groundwork, and neither an app nor Bluetooth is needed to open the compartment.
| Instabee in brief | |
|---|---|
| New locker compartments, installed in Sweden in August | 19,440 |
| In operation in Stockholm, fully solar powered today | 1 locker |
| Operating range, solar and battery power | −30 to 60 °C |
The design makes it possible to set up pick-up points faster and closer to where people live. After Sweden, the solution will be rolled out in the other markets ahead of the e-commerce peak season.
Source: Instabee Group, press release.
Kaunis Iron — talks with LKAB about ore deliveries
Kaunis Iron and LKAB have opened talks about the Pajala-based company supplying iron ore to LKAB's pelletising plants — the first choice is Svappavaara, where the ore is already transferred from truck to rail today. "We are in dialogue," LKAB's CEO Johan Menckel tells Dagens industri — while also pointing out that the ore's composition must fit the pelletising plants' recipe.
| Kaunis Iron in brief | |
|---|---|
| Production 2025, iron ore products | 1.9 Mt |
| Environmental permit going forward | 35 years |
| New open-pit mine, planned start of operations (not decided) | 2028 |
For Kaunis Iron it is about getting closer to the pellet market in Europe — freight costs have tripled since the company took over Northland Resources' bankruptcy estate, and today the entire production goes by train to Narvik and on to the world market.
Source: Dagens industri.
Eqvor — a new episode of Vägen till Exit
A poisonous mushroom that destroys the kidneys. A mushroom toxin that could become a treatment for kidney cancer. Börje Haraldsson is a physician and professor of nephrology with seven years at Novartis in Basel behind him. In 2011 he founded Oncorena in Gothenburg, and since 2022 he has been the company's CEO. In episode 14: the road from the toxin orellanine to the drug candidate ONC175, the phase 1/2 study at Karolinska and what it actually takes to prove efficacy.
Available on Spotify, Apple Podcasts and wherever you usually listen to podcasts.
Source: Eqvor.
